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Abstract The use of nebulization for the administration of inhaled steroids plays an important role in asthma patients 
who are unable to use pressurized aerosol or dry-powder inhalers effectively Moreover; the type of nebulizer used may 
affect how much drug is delivered to the lungs. The objective of this multinational, multicentre, randomized, active- 
controlled, parallel-group study was to compare the efficacy and safety of nebulized corticosteroids in adult patients with 
chronic asthma, Following a l-week placebo run-in period, 205 patients, aged l8-65years, with moderate persistent 
asthma were randomized to one of two treatment groups for I 2 weel<s: beclometasone dipropionate (BDP) suspension 
for nebulization 2400 pg day’ b.i.d. (n= 103) or fluticasone propionate (FP) suspension for nebulization 2000 pg day’ b.i.d. 
(n= IO2), both administered by a jet nebulizeu: Comparable efficacy in controlling asthma was demonstrated by the two 
treatments at study end, as evident when evaluating various efficacy parameters (pulmonary function tests, asthma 
exacerbations and symptoms, and the use of rescue salbutamol).The primary efficacy endpoint was the variation in the 
pulmonary expiratory flow (PEF) at treatment end over the baseline visit. For the intent-to-treat population, in the BDP 
group mean PEF values increased statistically significantly from 5.2 f I .3 I s-I to 5.7 * I .6 I s-1, while in the FP group the 
increase was from 5.2 k I .2 I s-l to 5.8 + I .8 I s-l. Mean PEF values as per cent of predicted also increased in a statistically 
significant way from 7 I % to 77. I % in the BDP group, and from 70. I % to 76.9% in the FP group.The two treatments were 
equally well to1erated.A total of 23 and 32 patients in the BDP and FP groups, respectively, reported adverse events during 
the treatment period, and these were generally mild. In conclusion, the results of this study demonstrate that BDP 
2400 I-18 day’ and FP 2000 pg day’, both suspensions for nebulization administered via a jet nebulizer; are equally effective, 
with an acceptable safety and tolerability profile, when used in adult patients with moderate persistent asthma. 
0 2003 Elsevler Science Ltd 
INTRODUCTION 
Nebulization of inhaled corticosteroids plays an 
important role in the management of asthma patients 
who cannot use other delivery systems effectively. 
Several clinical trials have shown that both beclo- 
metasone dipropionate (BDP) and fluticasone 
propionate (FP) are effective and well tolerated in the 
management of asthma. Moreover, studies comparing 
these corticosteroids when administered using a 
pressurized metered-dose inhaler (pMDI) have 
demonstrated equivalent clinical efficacy when used in 
children and adults with asthma of varying severity (2-7). 
However, to date direct comparison of BDP and FP 
suspensions for nebulization has not been reported.The 
purpose of this study was to compare the efficacy and 
safety of BDP and FP suspensions for nebulization 
administered via a new jet nebulizer in adult patients 
with moderate persistent asthma.The jet nebulizer was 
used on the basis of a previous study in which both BDP 
and FP were delivered via nebulization with a mean 
MMAD (mass mean aerodynamic diameter) of 2.6 + 0.2. 
MATERIALS AND METHODS 
Male and female outpatients, aged 18-65 years, with a 
clinical diagnosis of moderate persistent asthma (as 
defined by the National Heart, Lung and Blood 
Institute/World Health Organization), peak expiratory 
flow (PEF) between 60% and 80% of predicted normal 
value, a positive response to the reversibility test 
[defined as an increase of 15% in forced expiratory 
volume in I second (FEV,) measured 30 minutes after a 
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bronchodilator dose of salbutamol spray given via an 
MDI at the screening and baseline visits], and study 
medication compliance of 85% during the placebo run-in 
period were eligible to participate in the study. Patients 
with chronic obstructive pulmonary disease, a history or 
current evidence of heart failure and ischaemic heart 
disease, myocardial infarction/percutaneous transluminal 
coronary angioplasty/coronary artery bypass grafts within 
the previous 6 months, haemodynamic relevant rhythm 
disturbances, clinically significant or unstable concurrent 
diseases, or intolerance to the study drugs and/or their 
constituents, or who received oral or parenteral steroids 
or investigational new drugs in the previous I2 weeks, 
were excluded from the randomization. 
Study design 
This was a I3-week, randomized, active-controlled study 
undertaken in two parallel groups at I I centres. Following 
a l-week placebo run-in period, patients who met study 
entry criteria were assigned by randomization to one of 
the two treatment groups for a treatment period of 
I2 weeks: BDP suspension for nebulization 2400 Kg day-’ 
b.i.d. (Clenil-A@, Chiesi Farmaceutici SpA, Italy), or FP 
suspension for nebulization 2000 pg day’ b.i.d. (Flixotide 
Nebules@, Allen & Hanburys, U.K.). Both drugs were 
administered using the Clenny Aerosol Nebulizer (Chiesi 
Farmaceutici SpA, Italy), and all patients were instructed 
in its use. Long-acting &-agonists, cromolyn sodium, 
nedocromil, methylxanthines, leukotriene modifiers, 
anticholinergics, antihistamines, and parenteral and oral 
corticosteroids were excluded. The use of short-acting 
&-agonists, and of inhaled corticosteroids during the run- 
in phase, only at the same daily dosage used during the 
previous 4 weeks, was permitted. Patients were assessed 
at various clinic visits during the study: on screening, at 
the baseline/randomization visit, and at 4 and I2 weeks 
post-randomization. 
Lung function measurements were conducted 
according to the ERS guidelines (8) at the same hour of 
the day, with a variation equal to +2 h compared with the 
baseline visit. Spirometric lung function parameters were 
measured at each clinic visit. The use of short-acting B2- 
agonists had to be withdrawn at least 8 hours before the 
tests.Three measurements were performed, and the best 
was reported.Asthma exacerbation was defined if one of 
the following criteria occurred: worsening of asthma 
symptoms, which required treatment with systemic 
steroids; a reduction in the morning PEF to >30% below 
the baseline value on 2 consecutive days; use of five 
inhalations of rescue medication on each of any 
3 consecutive days since the previous visit. Morning and 
evening PEFs were measured daily by patients using the 
Mini-Wright peak flow meter (Clement Clarke 
International, U.K.) at the same hour each day 
(8 + I a.m., and 7 -+ I p.m. when possible) and the best of 
three measurements recorded on a diary card. Diurnal 
and nocturnal asthma symptoms, rated on an eight-point 
scale (scores l-8) ranging from ‘poor’ to ‘excellent’, 
evaluation of activity and sleep, and the use of short-acting 
&-agonists were also assessed daily by patients and 
recorded on a diary card.The institutional review board 
for each treatment centre approved the protocol, and 
written informed consent was obtained from the patients. 
Assessments 
The primary efficacy endpoint was the variation in the 
PEF value assessed by the investigator at I2 weeks vs the 
baseline/randomization visit. Secondary efficacy variables 
were the number of exacerbations, FEV,, forced vital 
capacity (FVC), morning and evening PEFs, improvements 
in asthma symptoms, and daily consumption of short- 
acting j&agonists. Safety parameters included physical 
examination, vital signs (electrocardiograms (ECGs), 
blood pressure, and heart rate), routine blood and urine 
laboratory tests, and frequency, nature and severity of 
adverse events. 
Statistical analysis 
Sample size calculation was based on the criteria of 
equivalent efficacy between the two treatments (9), 
taking as clinically not relevant a difference between 
groups in PEF values of 10%. Considering that the mean 
expected value of final PEF (per cent of predicted) was 
75, with a common standard deviation of I7 and with an 
a error of 0.05 (two-sided test), a total sample of 186 
patents (93 per arm) will provide 85% power rejecting 
the null hypothesis in favour of the alternative one when 
a real difference between treatments will exist. 
Within-treatment comparisons for the variation of 
PEF value assessed by the investigator at week I2 vs 
baseline visit were analysed by the t test for paired 
samples, and between-treatment comparisons by means 
of the non-parametric Kruskal-Wallis test. 
When indicated, continuous secondary efficacy 
variables were analysed by the ANOVA (analysis of 
variance) model, and categorical variables were analysed 
comparing the two groups by the Chi-square test and, if 
necessary, by the Fisher’s exact test. 
A descriptive analysis was provided for all safety data, 
with absolute and relative frequencies demonstrated, 
together with the 95% confidence interval for each 
estimate. Changes from baseline of vital signs were 
analysed by the Student’s t test, while between-treatment 
differences were analysed by the Chi-square statistic 
(Fisher’s exact test) and within-treatment differences by 
the McNemar’s test. Significance testing was two-tailed, 
with cc error fixed at the 5% level. 
All randomized patients with baseline evaluation of 
each symptom and who received at least one dose of the 
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study medication were to be included in the ITT 
population analysis. Missing data were replaced with the 
LOCF (last observation carried forward) method, except 
in the analysis of the number of exacerbations, days and 




Of the 222 patients screened for the study, 205 were 
randomized: 103 to the BDP group, and IO2 to the FP 
group.Three patients (one in the BDP group and two in 
the FP group) were excluded from the efficacy analysis 
sample due to protocol violations at selection, and 20 
patients (7 in the BDP group and I3 in the FP group) 
were excluded from the PP analysis due to various 
reasons.The ITT population was therefore made up of 
202 patients (I 02 treated with BDP and IO0 with FP), 
and the PP population of 182 patients (95 treated with 
BDP and 87 with FP).Assessment of safety of the two 
treatments was based on 202 patients. Patient 
demography and values for lung function parameters at 
baseline were comparable for the two groups in the 
randomized population (Table I). 
Evaluation of efficacy: PEF 
Statistically significant increases in PEF measured by the 
investigator were reported over baseline in the ITT 
population for both treatment arms at study end, with 
mean values rising from 5.2 I s-1 to 5.7 I s-1 in the BDP 
group (P=O.O002), and from 5.2 I s-1 to 5.8 I s-1 in the FP 
group (P=O.O002), and with no significant difference 
found between the two groups (Figure I). Mean PEF 
values as per cent of predicted also increased in a 
statistically significant way from 7 I % to 77. I % in the BDP 
group (P=O.OOO I), and from 70. I % to 76.9% in the FP 
Baseline End of treatment Baseline End of treatment 
P = 0.0002 versus baseline P = 0.0002 VPJTUS baseline 
NS baween treatments NS between treatmenrs 
FIGURE I. Mean values for peak expiratory flow in the (a) intent-to-treat and (b) per protocol populations of adults with moderate 
persistent asthma at baseline and after I2 weeks of treatment with beclometasone diproplonate or fluticasone propionate suspensions 
for nebulization. 
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FIGURE 2. Mean changes over baseline rn forced expiratory volume in I second and forced vital capacity in the intent-to-treat 
population of adults with moderate persistent asthma after I2 weele of treatment with beclometasone dipropionate or flutlcasone 
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FIGURE 3. Mean values for (a) morning and (b) evening peal< expiratory flow in the Intent-to-treat population of adults with moderate 
persistent asthma at baseline, and after 4 and I2 weeks of treatment wrth beclometasone dipropionate or fluticasone propionate 
suspensions for nebulization 
group (P=O.O002) (NS between treatments). Similarly, in 
the PP population mean PEF values rose statistically 
significant from 5.3 I s-l to 5.7 I s-1 in the BDP group 
(WO.000 I), and from 5.2 I s-1 to 5.8 I s-1 in the FP group 
(P=O.O002), with the between-group difference again 
being non-significant (Figure I). Mean values as per cent 
of predicted also increased statistically significantly from 
70.9% to 77.6% in the BDP group (P<O.OOOl), and from 
70.5% to 77.6% in the FP group (P=O.O003) (NS between 
treatments). 
Evaluation of efficacy: Number of 
exacerbations 
The number of patients who experienced asthma 
exacerbation was small in both treatment groups in the 
ITT analysis: two (2%) in the BDP group and five (5. I %) 
in the FP group, with no significant difference reported 
between the two treatment arms. 
Evaluation of efficacy: Other measures 
of pulmonary function 
At study end, significant mean changes of 0.3 litres were 
reported over baseline for both treatment groups in the 
ITT population for both FEV, and FVC, with no 
significant between-treatment difference being found for 
either parameter (Figure 2). 
Mean morning PEF values increased from 
359.2 I min-I at baseline to 383.7 I min-1 at treatment 
end in the BDP group, and from 357.8 to 384.2 I min-1 
in the FP group, with no significant difference found 
between the two groups (Figure 3). Similar results were 
seen for mean evening PEF values, which rose from 
379.3 I min-’ at baseline to 405.2 I mink at the end of 
treatment for BDP-treated patients, and from 377.8 to 
399.3 I min-1 in FP-treated patients, again with no 
significant between-treatment difference noted 
(Figure 3). 
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Evaluation of efficacy: Signs and 
symptoms and rescue medication 
In the ITT population, significant improvements in asthma 
symptoms over baseline were noted for both treatment 
groups at the end of the study. The number of patients 
reporting symptoms scores defined as ‘excellent’ rose 
from I6 (15.7%) at baseline to 54 (52.9%) at treatment 
end in the BDP group, and from I2 (I 2%) to 46 (46%) in 
the FP group, with the difference between the two 
groups being non-significant.When examining the means 
of the symptoms scores sum, values increased 
statistically significantly from 4.7 at baseline to 6.3 at 
treatment end in the BDP group (P<O*OO I), and from 4.6 
to 6.3 in the FP group (PcO=OOl), with no significant 
difference found between the two treatments. 
The number of symptom-free patients during the day 
(symptom score 0) increased significantly for the two 
groups at study end vs before treatment: from I3 
patients to 43 in the BDP group, and from IO to 35 in the 
FP group. No significant between-group difference was 
found. Similarly, notable increases were also reported for 
the two groups in the number of symptom-free patients 
during the night, rising from 22 to 5 I in the BDP group, 
and from 2 I to 48 in the FP group. Again, no significant 
difference was noted between the two treatment arms. 
In the BDP group, the use of salbutamol as rescue 
medication was reduced from an average of 
2.8 puffs day’ during the run-in period to 2.2 puffs day-1 
during the first 4 weeks of treatment, and then again to 
2-O puffs day-1 during the last 8 weeks. Similarly, patients 
treated with FP reduced their need for salbutamol from 
an average of 2.6 puffs day’ during the run-in phase to 
2.2 puffs day-’ during the initial 4 weeks of treatment, 
and again to 2. I puffs day’ during the final 8 weeks. No 
significant difference was found between the two 
treatment groups. 
Evaluation of safety 
Safety data showed that both treatments were well 
tolerated. During the treatment period, 23 (22.5%) 
patients in the BDP group and 32 (32%) in the FP group 
reported one or more adverse events (Table 2). The 
number of adverse events reported was 30 (39.5%) and 
46 (60.5%) in the BDP and FP groups, respectively, and 
these were generally mild (NS between treatments for 
both variables). In total, six patients reported adverse 
drug reactions: two (2%) in the BDP group, and four (4%) 
in the FP group, with two (25%) and six (75%) adverse 
drug reactions seen in the respective groups (NS 
between treatments for both parameters). Furthermore, 
only one patient (0.9%) in the BDP group discontinued 
treatment due to treatment-related adverse events. 
Moreover, no significant difference was found between 
the two treatments with regard to laboratory tests, and 
no clinically relevant changes in vital signs or physical 
examination were observed in either treatment group. 
DISCUSSION 
Inhaled corticosteroids are very effective in controlling 
symptoms in asthmatic patients of all ages and disease 
severity (IO).A number of previous clinical studies have 
compared the effects of specific corticosteroids, efficacy 
having been assessed for a wide range of doses in terms 
of reduction of symptoms and exacerbations, 
improvement of lung function, and a decreased need for 
bronchodilator rescue therapy (I I). 
A very important study involving BDP and FP 
compared multiple doses of FP (100-800 pg day-’ by 
pMDI) with a single dose of BDP (400 pg day-’ by pMDI) 
in 672 patients (2). A flat dose-response curve of lung 
function was seen, with no statistically significant 
differences in clinical efficacy between any dose of FP 
compared with the single dose of BDP nor between the 
various doses of FPThe authors concluded that 400 ,ug 
BDP pMDl was equivalent to 2OOug FP pMDI. An 
important study comparing BDP (I 600 pg day-i) and FP 
(2000 ug day’), both delivered by pMDI, showed that the 
two were similar in improving the efficacy of asthma 
control when prescribed to 134 patients who had 
previously received a lower dose of inhaled cortico- 
steroid (3). Another study in 274 adults found that 
treatment with 1500 ygdayr FP pMDl resulted in 
significantly higher morning and evening PEF values and 
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fewer exacerbations than the same dose of BDP pMDl 
(4).Three studies have compared BDP with half the dose 
of FP; no difference in clinical effect was found between 
the two treatments in any of them. One compared BDP 
(400 pg day’) and FP (200 pg day-r), both given by pMDl 
with plastic spacer to 398 children with asthma (5). 
Another compared BDP (2000 ,ugday-1) and FP 
(I 000 yg day-l) in I54 adults with severe asthma (6).The 
third compared BDP (400 pg day’) and FP (200 pg day-r), 
both given by pMDl to 261 adult patients with mild to 
moderate asthma (7). 
Based on these studies comparing BDP and FP 
delivered via pMDI, it is not possible to draw any firm 
conclusion about the comparative potencies of BDP and 
Fl? Furthermore, comparisons between the effects of 
BDP and FP delivered via nebulizer have not previously 
been available. Therefore, ours is the first study that 
compares, in asthmatic patients, the clinical effects of 
BDP and FP delivered via a jet nebulizer, adding to our 
two recently published studies: flunisolide 500 pg vs 
budesonide 500 pg, both administered twice-daily by jet 
nebulizer for 4 weeks in I33 children (I 2), and BDP 
800 pg day’ b.i.d. or budesonide IO00 pg day’ b.i.d. 
both administered by jet nebulizer in 127 children with 
mild to moderate persistent asthma (I 3). Both studies 
highlight the equivalent clinical responses and good 
safety profiles of nebulized corticosteroids in children. 
This study demonstrates that suspension for 
nebulization forms of BDP 2400 pg day-’ and FP 
2000 pg day-r, given via a jet nebulizer, are effective and 
therapeutically equivalent and have a good safety and 
tolerability profile when used to control moderate 
persistent asthma in adult patients. Corticosteroids 
delivered via nebulizer may be an effective and attractive 
alternative to pMDls, especially when it is necessary to 
administer high doses of drug (>500 pg), and to avoid 
problems related to poor hand-respiration coordination 
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